JP2018090572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018090572A5 JP2018090572A5 JP2017225340A JP2017225340A JP2018090572A5 JP 2018090572 A5 JP2018090572 A5 JP 2018090572A5 JP 2017225340 A JP2017225340 A JP 2017225340A JP 2017225340 A JP2017225340 A JP 2017225340A JP 2018090572 A5 JP2018090572 A5 JP 2018090572A5
- Authority
- JP
- Japan
- Prior art keywords
- salts
- group
- menthol
- tablet
- sedating antihistamines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 9
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 2
- 239000000938 histamine H1 antagonist Substances 0.000 claims 2
- 229940041616 menthol Drugs 0.000 claims 2
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 claims 1
- CMCCHHWTTBEZNM-UHFFFAOYSA-N 2-bromo-N-carbamoyl-3-methylbutanamide Chemical compound CC(C)C(Br)C(=O)NC(N)=O CMCCHHWTTBEZNM-UHFFFAOYSA-N 0.000 claims 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims 1
- 239000004376 Sucralose Substances 0.000 claims 1
- KSUUMAWCGDNLFK-UHFFFAOYSA-N apronal Chemical compound C=CCC(C(C)C)C(=O)NC(N)=O KSUUMAWCGDNLFK-UHFFFAOYSA-N 0.000 claims 1
- 229960004459 apronal Drugs 0.000 claims 1
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 claims 1
- 229960002071 bepotastine Drugs 0.000 claims 1
- 229960003880 bromisoval Drugs 0.000 claims 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 1
- 229960001971 ebastine Drugs 0.000 claims 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 claims 1
- 229960003449 epinastine Drugs 0.000 claims 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 claims 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 claims 1
- 229960000514 ethenzamide Drugs 0.000 claims 1
- 229960003592 fexofenadine Drugs 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims 1
- 229960004949 glycyrrhizic acid Drugs 0.000 claims 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims 1
- 239000001685 glycyrrhizic acid Substances 0.000 claims 1
- 235000019410 glycyrrhizin Nutrition 0.000 claims 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960001508 levocetirizine Drugs 0.000 claims 1
- 229960003088 loratadine Drugs 0.000 claims 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 1
- 229960002373 loxoprofen Drugs 0.000 claims 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 claims 1
- 229960004114 olopatadine Drugs 0.000 claims 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 claims 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims 1
- 229960003908 pseudoephedrine Drugs 0.000 claims 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 1
- 235000019408 sucralose Nutrition 0.000 claims 1
- 239000000341 volatile oil Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022000850A JP7243876B2 (ja) | 2016-11-29 | 2022-01-06 | 固形製剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016230737 | 2016-11-29 | ||
| JP2016230737 | 2016-11-29 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000850A Division JP7243876B2 (ja) | 2016-11-29 | 2022-01-06 | 固形製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018090572A JP2018090572A (ja) | 2018-06-14 |
| JP2018090572A5 true JP2018090572A5 (https=) | 2020-12-24 |
| JP7077589B2 JP7077589B2 (ja) | 2022-05-31 |
Family
ID=62563583
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017225340A Active JP7077589B2 (ja) | 2016-11-29 | 2017-11-24 | 固形製剤 |
| JP2022000850A Active JP7243876B2 (ja) | 2016-11-29 | 2022-01-06 | 固形製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000850A Active JP7243876B2 (ja) | 2016-11-29 | 2022-01-06 | 固形製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP7077589B2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019026644A (ja) * | 2017-08-01 | 2019-02-21 | ロート製薬株式会社 | 医薬用錠剤 |
| JP7780242B2 (ja) * | 2018-02-26 | 2025-12-04 | ロート製薬株式会社 | フェキソフェナジン塩酸塩を含む造粒物 |
| JP7472540B2 (ja) * | 2019-03-19 | 2024-04-23 | 大正製薬株式会社 | 固形組成物 |
| JP7667528B2 (ja) * | 2020-04-15 | 2025-04-23 | 大正製薬株式会社 | 医薬組成物 |
| JP7709112B2 (ja) * | 2020-04-15 | 2025-07-16 | 大正製薬株式会社 | 医薬組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0762869A1 (en) * | 1994-06-03 | 1997-03-19 | The Procter & Gamble Company | Fast dissolving dosage forms |
| JP4300652B2 (ja) * | 1998-09-21 | 2009-07-22 | 大正製薬株式会社 | 経口用固形製剤 |
| WO2007011018A1 (ja) * | 2005-07-22 | 2007-01-25 | Mitsubishi Tanabe Pharma Corporation | 口腔内速崩壊性錠 |
| BRPI1012170A2 (pt) * | 2009-05-20 | 2016-03-29 | Lingual Consegna Pty Ltd | formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido. |
| CN103547265B (zh) | 2011-04-28 | 2017-11-21 | 田边三菱制药株式会社 | 口腔内速崩片 |
| JP6062705B2 (ja) | 2012-10-19 | 2017-01-18 | ロート製薬株式会社 | 医薬組成物 |
| JP6227546B2 (ja) | 2012-10-26 | 2017-11-08 | 田辺三菱製薬株式会社 | メントールウィスカーの析出を抑制する方法 |
| JP6184727B2 (ja) * | 2013-04-15 | 2017-08-23 | ロート製薬株式会社 | 医薬組成物 |
-
2017
- 2017-11-24 JP JP2017225340A patent/JP7077589B2/ja active Active
-
2022
- 2022-01-06 JP JP2022000850A patent/JP7243876B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018090572A5 (https=) | ||
| DOP2017000306A (es) | Formulaciones farmacéuticas que contienen tenofovir y emtricitabina | |
| DE602004017510D1 (de) | Medizinprodukt vom kapseltyp | |
| CY1121462T1 (el) | Ακυλιωμενα αναλογα γλυκαγονης | |
| EA201201263A1 (ru) | Фармацевтическая композиция, содержащая этексилат дабигатрана | |
| CY1115544T1 (el) | Σκευασμα καψουλων πιρφενιδονης και αποδεκτων φαρμακευτικως εκδοχων | |
| JP2014221779A5 (https=) | ||
| CY1111934T1 (el) | Σταθεροποιημενες φαρμακευτικες συνθεσεις οι οποιες περιεχουν φεσοτεροδινη | |
| IL283539A (en) | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | |
| CY1113178T1 (el) | Σταθεροποιημενες αμορφες μορφες της μεσυλικης ιματινιβης | |
| EA201201202A1 (ru) | Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана | |
| BRPI0807285A2 (pt) | "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto" | |
| IL290447A (en) | Pharmaeutical composition comprising ensifentrine | |
| EP4051285A4 (en) | Pharmaceutical unit dose systems for oral dry solution and suspension | |
| IL274456A (en) | Inhibitor of expression of pro-carcinogenic factors, screening method for an active ingredient thereof, expression cassette used in this method, diagnostic drug and diagnostic method | |
| EP4045048A4 (en) | ORAL FORMULATIONS WITH SITAGLIPTIN HCI MONOHYDRATE WITH IMPROVED PHARMACEUTICAL PROPERTIES | |
| IL283721A (en) | Colonic drug delivery formulation | |
| ES2680293B1 (es) | Composición farmacéutica que comprende ácido 2,5 - dihidroxibencenosulfónico o una de sus sales farmacéuticamente aceptables en forma de unidades individualizadas de suministro y procedimiento de fabricación correspondiente | |
| IL271628B1 (en) | A new salt of n-(6,2-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-5,4-dihydro-1h -pyrazolo[3,4-h]quinazoline-3-carboxamide, its preparation and formulations containing it | |
| CN105764509A (zh) | 达比加群酯或其盐的投药制剂及其制备方法 | |
| CN109661386A (zh) | 沙库比曲钠盐新晶型 | |
| UA46099S (uk) | 1.-3. розгортка упаковки для лікарського засобу | |
| WO2013144976A3 (en) | Chewable soft gelatin capsule dosage form of mucolytic agents | |
| ZA202103380B (en) | Substituted 1,2,4-oxadiazole, its application and a pharmaceutical preparation comprising it | |
| EP3986267A4 (en) | ORAL ECG DEVICE |